Evidence map›Paper›PMID 41623602›Full record

ReviewJournal of the anus, rectum and colon2026

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2024 for the Clinical Practice of Inflammatory Bowel Disease-Associated Intestinal Neoplasia (English Version).

Soichiro Ishihara, Shinji Tanaka, Toshio Uraoka, Yutaka Saito, Hiroyuki Takamaru, Hiroshi Nakase, Makoto Naganuma, Tadakazu Hisamatsu, Toshimitsu Fujii, Minoru Matsuura and 30 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the anus, rectum and colon, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Soichiro IshiharaDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shinji TanakaJA Onomichi General Hospital Onomichi and Department of Gastroenterology, Hiroshima University, Hiroshima, Japan.
Toshio UraokaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Gunma University, Maebashi, Japan.
Yutaka SaitoEndoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Hiroyuki TakamaruEndoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Hiroshi NakaseDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Makoto NaganumaDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Tadakazu HisamatsuDepartment of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
Toshimitsu FujiiDepartment of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.
Minoru MatsuuraDepartment of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
Takayuki MatsumotoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, School of Medicine, Iwate, Japan.
Kenji WatanabeDepartment of Internal Medicine for Inflammatory Bowel Disease, University of Toyama, Toyama, Japan.
Hiroki IkeuchiDivision of Inflammatory Bowel Disease Surgery, Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
Motoi UchinoDivision of Inflammatory Bowel Disease Surgery, Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan.
Yoshiki OkitaDepartment of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan.
Koji OkabayashiDivision of Colorectal Surgery, Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Kazutaka KoganeiDepartment of Inflammatory Bowel Disease, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Akira SugitaDepartment of Inflammatory Bowel Disease, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Kenichi TakahashiDepartment of Colorectal Surgery, Tohoku Rosai Hospital, Sendai, Japan.
Keisuke HataDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Daijiro HigashiDepartment of Surgery, Fukuoka University Chikushi Hospital, Chikushino, Japan.
Kitaro FutamiDepartment of Surgery, Matsunaga Hospital, Fukuoka, Japan.
Keiji MatsudaDepartment of Surgery, The Fraternity Memorial Hospital, Tokyo, Japan.
Tsunekazu MizushimaDepartment of Colorectal Surgery, Dokkyo Medical University, Mibu, Japan.
Yusuke WatadaniDepartment of Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiroshi KawachiDepartment of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Masayuki ShimodaDepartment of Pathology, The Jikei University School of Medicine, Tokyo, Japan.
Tamotsu SugaiDepartment of Molecular Diagnostic Pathology, Iwate Medical University School of Medicine, Iwate, Japan.
Masahiro YoshidaDepartment of Hepato-Biliary-Pancreatic and Gastrointestinal Surgery, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan.
Naohiko YamaguchiLibrary of Seirei Sakura Citizen Hospital, Sakura, Japan.
Michio ItabashiSaitama Saiseikai Kazo Hospital, Kazo, Japan.
Hiroyuki AnzaiDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Junko KishikawaDepartment of Surgery, Tohto Bunkyo Hospital, Tokyo, Japan.
Koichi KomatsuDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takahide ShinagawaDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tatsuya TsushimaDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tatsuki NoguchiDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Satoshi OkadaDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kenichi SugiharaInstitute of Science Tokyo, Tokyo, Japan.
Yoichi AjiokaDivision of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The number of patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), continues to increase in many countries and regions. With recent rapid advances in medical therapies targeting intestinal inflammation, the number of patients with long-term disease duration is also increasing. It is well-recognized that longstanding IBD carries an increased risk of developing gastrointestinal (GI) neoplasia, particularly colorectal cancer. However, compared to sporadic GI tumors, IBD-associated GI tumors are relatively rare, and even among specialists in GI diseases, opportunities to encounter such cases remain limited. In light of this situation, the Japanese Society for Cancer of the Colon and Rectum (JSCCR), in collaboration with the Japanese Inflammatory Bowel Disease Research Group (funded by the Japan Sciences Research Grant for Research on Intractable Diseases affiliated with the Ministry of Health, Labour, and Welfare) launched the Guideline Development Committee for IBD-associated Gastrointestinal Tumors in 2021, with the aim of establishing clinical practice guidelines to support the diagnosis and management of these tumors. The committee-comprising experts in gastroenterology, surgery, pathology, guideline development, and literature review-conducted extensive discussions and successfully published the first Japanese edition of the guidelines in July 2024. We believe that the current edition provides the best possible guidance based on presently available knowledge. Furthermore, the guideline development process highlighted several key issues to be addressed in future research and clinical practice. We are pleased to present here the English version of the JSCCR Guidelines 2024 for the Clinical Practice of IBD-associated Intestinal Neoplasia.

Indexed as

anorectal cancercolorectal cancerdysplasiaguidelinesinflammatory bowel diseasesmall bowel cancer

Identifiers

PMID41623602
PMCPMC12854282

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.